Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 20 November 2012 | By Alexander Gaffney, RAC,
Animal drug products may not be expected to meet the same standards for safety and efficacy as their human-intended counterparts, but that doesn't mean that their eventual recipients don't appreciate a product that's easy on both their taste buds and sense of smell.
That's the finding of a new draft guideline out from the European Medicines Agency (EMA), On the Demonstration of Palatability of Veterinary Medicinal Products, which lays out the requirements for veterinary products where a good-tasting or -smelling product is necessary for the drug to be effective.
The old adage, "You can lead a horse to water, but you can't make him drink," is perhaps as fitting as any. EMA explains in the guidance that "voluntary uptake"-i.e. the animal actually wants to consume the medicine-is a positive quality for a medicine to have.
Much like medicines for children, flavoring components are often mixed in with the drug product, increasing the chance of voluntary update by improving its palatability.
But be warned, said EMA: Your oral-dose veterinary product may be delicious or smell like roses, but you're still going to have to prove it-with data, no less.
"For oral formulations intended for group treatment, correct uptake of the medicated food or water is a prerequisite for sufficient exposure and thus effective treatment," EMA explained. Original products have this requirement built into their approval process-if it's not palatable, it's unlikely to be approved-but EMA implied that it remains concerned that generic formulations could have a different palatability profile capable of affecting the uptake of the medicine.
So what are some of the factors that make a product palatable? Shape, size, texture, density, and color, to name a few. Anyone who's ever been required to ingest a pill more similar in size to a golf ball than an M&M can likely envision why some of those factors might be relevant.
But beyond qualitative feelings, EMA said it wants hard data to support palatability assessments.
In vivo studies will be required for palatability studies, which may differ between animals in controlled conditions and those under field conditions, as well as between sick and healthy animals. Endpoints to be considered in a palatability study include time to uptake, completeness of uptake, regurgitation, consumption only when hidden, need for non-voluntary administration and outright refusal by the animal subjects.
EMA defines voluntary acceptance as "good" if "most of the animals will voluntarily ingest the complete dose throughout the entire course of therapy."
Studies may be waived for generic products if they are "qualitatively and quantitatively comparable to the reference product"-undefined by EMA, but likely meaning an exact copy of the original veterinary product.
Comments on the guideline are due by 31 May 2013.
Tags: Smell, Taste, Palatability, Animal, Veterinary, Latest News, pharmaceutical, drug
Regulatory Focus newsletters
All the biggest regulatory news and happenings.